La cadena de opciones muestra datos clave de las opciones de acciones de Oncology Institute a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Oncology Institute..

Oncology Institute (NASDAQ:TOI) Bolsa, Cadena de Opciones

Oncology Institute

The Oncology Institute

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

The Oncology Institute, Inc. - Common Stock

The Oncology Institute Inc

THAI OIL PCL FGN REG SHS by Thai Oil Public Co., Ltd.

Thai Oil PCL

THAI OIL PCL UNSP/ADR by Thai Oil Public Co., Ltd.

TOPICUS COM INC SUB VTG by TOPICUS COM INC.

Topicus com Inc

KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.87) by 5.75 percent. This is a 9.52 percent decrease over losses of $(0.84) per share from the same period last year.

Earnings

News

KALV

KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M

WIIM

VSTE

Vast Renewables shares are trading higher after the company received up to AUD180M in conditional funding from the Australian Renewable Energy Agency for its Port Augusta clean energy project.

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and raises the price target from $7 to $7.25.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Endeavour Silver, Raises Price Target to $7.25

For Q1 2025:
<ul>
<li>Consolidated revenue from continuing operations (which includes Power discrete and Power IC businesses, and excludes our former Display business) to be in the range of $42 to $47 million, down 8.9% sequentially due primarily to seasonality, but up 11.5% year-over-year at the mid-point. This compares with equivalent revenue of $48.9 million in Q4 2024 and $39.9 million in Q1 2024.</li>
<li>Consolidated gross profit margin from continuing operations to be in the range of 18.5% to 20.5%, due to the seasonal sequential decline in revenue and the wind down of Transitional Foundry Services impacting fab utilization. This compares with equivalent gross profit margin of 23.2% in Q4 2024 and 17.6% in Q1 2024.</li>
</ul>

Guidance

Magnachip Expects Q1 Revenue From Continuing Operations Of $42M-$47M, Up 11.5% YoY

Financing

Vast Renewables Limited Receives Up To AUD180M Of Conditional Funding From Australian Renewable Energy Agency For Construction Of Its Port Augusta Utility-Scale Clean Energy Project

Full-Year 2025 Guidance
In 2025, the Company expects to generate Adjusted EBITDA between $1.6 billion and $2.2 billion and Adjusted EBIT between $350 million and $950 million.

ZIM Integrated Shipping Services 2025 Outlook: Expects Adjusted EBITDA Of $1.6B-$2.2B And Adjusted EBIT Of $350M-$950M

AMRN

Amarin Intends To Effect Ratio Change On ADSs From One ADS Representing One Ordinary Share To New Ratio Of One ADS Representing 20 Ordinary Shares

HC Wainwright &amp; Co. analyst Scott Buck reiterates Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Buy and maintains $26 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Redwire, Maintains $26 Price Target

Stock Split

Amarin To Effect An ADS Ratio Change From One ADS Representing One Ordinary Share To One ADS Representing Twenty Ordinary Shares

Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 76.92 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $143.537 million which missed the analyst consensus estimate of $162.060 million by 11.43 percent. This is a 13.18 percent decrease over sales of $165.318 million the same period last year.

Earnings Misses

Solo Brands Q4 2024 Adj. EPS $0.03 Misses $0.11 Estimate, Sales $143.537M Miss $162.060M Estimate

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $1.95 million which beat the analyst consensus estimate of $1.82 million by 7.29 percent. This is a 10.68 percent increase over sales of $1.76 million the same period last year.

NSPR

InspireMD Q4 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $1.95M Beat $1.82M Estimate

Earnings Beats

HBIO

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Buy and maintains $6 price target.

EVEX

HC Wainwright & Co. Reiterates Buy on Eve Holding, Maintains $6 Price Target

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $62.31 million which beat the analyst consensus estimate of $35.92 million by 73.48 percent. This is a 16.61 percent decrease over sales of $74.71 million the same period last year.

Amarin Corp Q4 2024 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $62.31M Beat $35.92M Estimate

Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.45 by 2.22 percent. This is a 13.21 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $14.07 million which missed the analyst consensus estimate of $15.81 million by 11.02 percent. This is a 5.20 percent decrease over sales of $14.84 million the same period last year.

REFI

Chicago Atlantic Real Q4 Adj $0.46 Beats $0.45 Estimate, Sales $14.07M Miss $15.81M Estimate

Biotech

General

RDHL

RedHill Biopharma Initiates Phase 2 Study Of RHB-204 In Mycobacterium Avium Subspecies Paratuberculosis-Positive Moderate To Severe CD

Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.51 by 9.8 percent. The company reported quarterly sales of $287.49 million which beat the analyst consensus estimate of $265.88 million by 8.12 percent.

SDHC

Smith Douglas Homes Q4 2024 GAAP EPS $0.46 Misses $0.51 Estimate, Sales $287.49M Beat $265.88M Estimate

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.78 by 11.54 percent. This is a 1.16 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $2.11 billion which beat the analyst consensus estimate of $2.09 billion by 1.07 percent. This is a 2.17 percent increase over sales of $2.07 billion the same period last year.

ABM Indus Q1 2025 Adj EPS $0.87 Beats $0.78 Estimate, Sales $2.11B Beat $2.09B Estimate

iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) reported quarterly losses of $(2.06) per share which missed the analyst consensus estimate of $(1.73) by 19.08 percent. This is a 13.19 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $172.03 million which beat the analyst consensus estimate of $171.00 million by 0.60 percent. This is a 44.06 percent decrease over sales of $307.54 million the same period last year.

IRBT

iRobot Q4 Adj $(2.06) Misses $(1.73) Estimate, Sales $172.03M Beat $171.00M Estimate

ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) reported quarterly earnings of $4.66 per share which beat the analyst consensus estimate of $3.49 by 33.52 percent. This is a 478.86 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $2.17 billion which beat the analyst consensus estimate of $2.06 billion by 5.33 percent. This is a 79.92 percent increase over sales of $1.21 billion the same period last year.

Comments

Oncology Institute

Oncology Institute (TOI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL